US FDA clears new Merck drug for hepatitis C

Merck & Co won US approval on Friday to sell a new drug considered a major advance against the liver-destroying hepatitis C virus.
Victrelis is expected to help transform treatment of the potentially fatal disease with higher cure rates and shorter courses of therapy for some patients.
Subscribe for our daily newsletter
Subscribe for our daily newsletter

By subscribing I accept the terms of use and privacy policy

Read all Tweets >